Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease

被引:1
作者
Ulloa, Jorge H. [1 ]
Lurie, Fedor [2 ]
Santiago, Fabricio R. [3 ]
Gianesini, Sergio [4 ]
Lourdes, Reina [5 ]
Wang, Jinsong [6 ]
Jindal, Ravul [7 ]
Taha, Wassila [8 ]
Bokuchava, Mamuka [9 ]
Mansilha, Armando [10 ]
机构
[1] Santa Fe Univ Hosp Fdn, Dept Vasc Surg, Med Assoc Andes, Cra 9 116-20,Cons 910, Bogota, Colombia
[2] Jobst Vasc Inst, Div Vasc Surg, Toledo, OH USA
[3] Inst Venous Dis, Goiania, GO, Brazil
[4] Univ Ferrara, Ferrara, Italy
[5] Cruz Roja Hosp, Unit Vasc Surg, Madrid, Spain
[6] Guangdong Prov Peoples Hosp, Dept Vasc & Plast Surg, Guangzhou, Peoples R China
[7] Fortis Hosp Mohali, Dept Vasc Surg, Mohali, Punjab, India
[8] Al Salam Hosp, Vasc Lab, Cairo, Egypt
[9] Bokhua Mem Cardiovasc Ctr, Tbilisi, Georgia
[10] S Joao Univ Hosp, Dept Vasc Surg, Porto, Portugal
关键词
Quality of life; Venous insufficiency; Therapeutics; PURIFIED FLAVONOID FRACTION; DOUBLE-BLIND; CALCIUM DOBESILATE; RUSCUS-ACULEATUS; VARICOSE-VEINS; PLACEBO; INSUFFICIENCY; DISORDERS; EFFICACY; SYMPTOMS;
D O I
10.23736/S0392-9590.23.05108-8
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Introduction: Chronic venous disease (CVD) can lead to considerable morbidity and impact health-related quality of life (HRQoL). The aim of this review was twofold: (i) to provide a deeper understanding of how CVD affects HRQoL (physical, psychological and social functioning), and (ii) to review the impact of evidence-based veno-active drugs (VADs) on HRQoL. Evidence acquisition: For the effect of CVD on HRQoL, information was gathered during an Expert Consensus Meeting, during which data were presented from both the patient and physician perspective assessed with validated quality-of-life measures. For the impact of VADs on HRQoL, a systematic literature review was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic databases were searched for real world evidence or randomized-controlled trials (RCT) vs. placebo, reporting data on the influence of VADs on HRQoL in patients with CVD. Evidence synthesis: CVD can negatively affect daily life in a number of areas related to pain, physical function and social activities. The impact of CVD on HRQoL begins early in the disease and for patients the emotional burden of the disease is as high as the physical burden. In contrast, physicians tend to overestimate the physical impact. The database search yielded 184 unique records, of which 19 studies reporting on VADs and HRQoL in patients with CVD met the inclusion criteria (13 observational and 6 RCTs). Micronized purified flavonoid fraction (MPFF) was the most represented agent, associated with 12/19 studies (2 RCTs and 10 observational). Of the 6 RCTs, only MPFF, aminaphthone and low-dose diosmin provided statistically significant evidence for improvement on HRQoL compared with placebo; for the other VADs improvements in HRQoL were not statistically different from placebo. MPFF was also associated with improvements in HRQoL in the observational studies, across all CEAP clinical classes, as monotherapy or in combination with other conservative therapy, and for all aspects of HRQoL: physical, psychological, and social. Real-world data for the other VADs were scarce. Ruscus extract, sulodexide and a semi-synthetic diosmin were each represented by a single observational study and these limited data were associated with statistically significant improvements compared with baseline in overall and subdomain scores across the range of CEAP clinical classes. Conclusions: CVD can impair patients' HRQoL significantly at all stages of the disease. MPFF has the greatest evidence base of clinical use in both RCT and real-world observational studies for effectiveness on HRQoL and is recognized by international guidelines. (Cite this article as: Ulloa JH, Lurie F, Santiago FR, Gianesini S, Lourdes R, Wang J, et al. Systematic litera- ture review and expert meeting report on health-related quality of life in chronic venous disease. Int Angiol 2023 Nov 28. DOI: 10.23736/S0392-9590.23.05108-8)
引用
收藏
页码:465 / 476
页数:12
相关论文
共 67 条
[1]   Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial [J].
Belczak, Sergio Q. ;
Sincos, Igor R. ;
Campos, Walter ;
Beserra, Julio ;
Nering, Gilberto ;
Aun, Ricardo .
PHLEBOLOGY, 2014, 29 (07) :454-460
[2]   Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting [J].
Bogachev, Vadim ;
Boldin, Boris ;
Turkin, Pavel ;
Samenkov, Alexander ;
Dzhenina, Olga .
FUTURE CARDIOLOGY, 2022, 18 (10) :777-785
[3]   Management and evaluation of treatment adherence and effectiveness in chronic venous disorders: results of the international study VEIN Act Program [J].
Bogachev, Vadim ;
Arribas, Jose Manuel Jimenez ;
Baila, Sorin ;
Dominguez, Jorge Ulloa ;
Walter, Johannes ;
Maharaj, Dale ;
Marin, Andres .
DRUGS & THERAPY PERSPECTIVES, 2019, 35 (08) :396-404
[4]  
Bogachev VY, 2020, PHLEBOLYMPHOLOGY, V27, P70
[5]   Impact of chronic venous disease on quality of life: Results of vein alarm study [J].
Branisteanu, Daciana-Elena ;
Feodor, Toni ;
Baila, Sorin ;
Mitea, Iuliana-Alma ;
Vittos, Oana .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (02) :1091-1096
[6]   Modelling the effect of venous disease on quality of life [J].
Carradice, D. ;
Mazari, F. A. K. ;
Samuel, N. ;
Allgar, V. ;
Hatfield, J. ;
Chetter, I. C. .
BRITISH JOURNAL OF SURGERY, 2011, 98 (08) :1089-1098
[7]  
Correia Ricardo, 2021, Angiol Cir Vasc, V17, P252, DOI 10.48750/acv.424
[8]   Pathophysiology of pain in venous disease [J].
Danziger, N. .
JOURNAL DES MALADIES VASCULAIRES, 2007, 32 (01) :1-7
[9]   The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence [J].
Davies, Alun H. .
ADVANCES IN THERAPY, 2019, 36 (Suppl 1) :5-12
[10]   European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs [J].
De Maeseneer, Marianne G. ;
Kakkos, Stavros K. ;
Aherne, Thomas ;
Baekgaard, Niels ;
Black, Stephen ;
Blomgren, Lena ;
Giannoukas, Athanasios ;
Gohel, Manjit ;
de Graaf, Rick ;
Hamel-Desnos, Claudine ;
Jawien, Arkadiusz ;
Jaworucka-Kaczorowska, Aleksandra ;
Lattimer, Christopher R. ;
Mosti, Giovanni ;
Noppeney, Thomas ;
Josee van Rijn, Marie ;
Stansby, Gerry ;
Kolh, Philippe ;
Bastos Goncalves, Frederico ;
Chakfe, Nabil ;
Coscas, Raphael ;
de Borst, Gert J. ;
Dias, Nuno, V ;
Hinchliffe, Robert J. ;
Koncar, Igor B. ;
Lindholt, Jes S. ;
Trimarchi, Santi ;
Tulamo, Riikka ;
Twine, Christopher P. ;
Vermassen, Frank ;
Wanhainen, Anders ;
Bjorck, Martin ;
Labropoulos, Nicos ;
Lurie, Fedor ;
Mansilha, Armando ;
Nyamekye, Isaac K. ;
Ramirez Ortega, Marta ;
Ulloa, Jorge H. ;
Urbanek, Tomasz ;
van Rij, Andre M. ;
Vuylsteke, Marc E. .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2022, 63 (02) :184-267